MedTrace Logo

A Polysomnographic Study Of Single-Dose Gabapentin In Transient Insomnia

NCT00674752 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 377

Last updated 2021-02-02

No results posted yet for this study

Summary

The purpose of this study is to assess the effect of gabapentin on polysomnographic assessments in transient insomnia induced by a sleep phase advance.

Conditions

  • Transient Insomnia

Interventions

DRUG

Gabapentin

Gabapentin 250 mg oral capsule 30 minutes prior to bedtime

DRUG

Gabapentin

Gabapentin 500 mg oral capsule 30 minutes prior to bedtime

DRUG

Placebo

Matched placebo oral capsule 30 minutes prior to bedtime

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Completion
2006-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00674752 on ClinicalTrials.gov